The convergence of nanotechnology and medicine has filled a large gap in therapeutic
strategies, improving cancer treatment drastically. In this review paper, current …

Precise activation of polymer nanoparticles at lesion sites is crucial to achieve favorable
therapeutic efficacy. However, conventional endogenous stimuli-responsive polymer …

Sorafenib is the first line drug for hepatocellular carcinoma (HCC) therapy. However, HCC
patients usually acquire resistance to sorafenib treatment within 6 months. Recent …

Polyprodrug nanomedicines hold great potential for combating tumors. However, the
functionalization of polyprodrug nanomedicines to improve therapeutic efficacy is restricted …

Tyrosine kinase inhibitors represented by sorafenib are the first‐line treatment for
hepatocellular carcinoma (HCC), but the low response rate of HCC patient has become a …

In this study, we combined low pH and cathepsin B dual-stimulus-triggered delivery carriers
with a bioorthogonal reaction-activated prodrug to achieve regulated activation of the …

Lacking of substantial physiological activity and low utilization remains a problem for most
conventional drug carriers. Polyprenol with beneficial medical effects and high availability …

Advancements in the synthesis of sulfur‐rich materials are driving progress across diverse
fields owing to the rich and tunable functionalities of those materials. These materials are …

Polyprodrugs have attracted intense interest for tumor-specific chemotherapy, by
conjugating chemotherapeutic drugs via two dynamic covalent bonds in the polymer main …

摘要肿瘤是当前全球范围内的主要致死病因, 而化疗仍是抗肿瘤治疗的重要手段之一.
阿霉素(DOX) 是一种临床上广泛使用的蒽环类广谱抗肿瘤药物, 但是它的治疗效果受到其严重 …